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mortality. Immune mediated damage has been proposed as a pathogenic factor, but immune responses
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oronavirus Disease 19 (COVID-19) is a pandemic
respiratory disease with 2–3% lethality and a particularly
severe course in males, patients with cardiovascular
comorbidities, and in the elderly1, 2. Lymphopenia, high levels of
pro-inflammatory cytokines in the circulation3, and phenotypic
changes of pro-inflammatory macrophages in bronchoalveolar
lavages (BALs)4 in severe patients have led to the notion that the
immune response against the causative virus severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) may con-
tribute to devastating end-organ damage5. Since patients with
severe COVID-19 may develop acute respiratory distress syn-
drome (ARDS) and many patients die from respiratory failure
with diffuse alveolar damage6, it is critical to understand the
immunological profiles in the lungs of these patients.
In this work, we use histologic and transcriptomic analyses of
post mortem lung tissues in a cohort of patients where the cause
of death was respiratory failure. We describe two distinct
immunological and cellular profiles in the lungs of these patients,
defined by their differential expression of interferon-stimulated
genes (ISGs) and immune infiltration patterns. ISG subgroups
strongly differ in regards to the characteristics and the extent of
pulmonary damage, pulmonary viral loads, immune infiltration,
and time from hospitalization to death. These data highlight two
distinct patterns of immune pathology of pulmonary COVID-19
and may give insight into the natural progression of COVID-19
in the lungs.
Results
Two patterns of gene expression in COVID-19 autopsy lungs.
Here we analyzed 34 post mortem lung samples from 16 deceased
COVID-19 patients and 9 post mortem lung samples from 6
patients, who died from non-infectious causes (Table 1 and
Supplementary Table 1). The primary cause of death in all
patients of this cohort was respiratory failure, sometimes multi-
organ failure including failure of the respiratory system. Since
lung samples from the same patients did not always appear
morphologically uniform, all lung specimens were subjected to
differential gene expression analysis based on a commercially
available targeted next-generation sequencing (NGS) assay
(OIRRA) designed for the quantification of immune cell and
inflammatory transcripts (Supplementary Table 2). Among the
398 genes investigated, we identified 68 upregulated and 30
downregulated genes in COVID-19 infected lungs compared to
normal tissue (Fig. 1a, b and Supplementary Table 3), and a PCA
analysis showed segregation of COVID-19 patients in two well-
defined clusters that showed distinct association with viral load
(Fig. 1a, c).
Using a consensus of 30 different indices7, we identified three
groups of samples defined by distinct expression levels of the
deregulated genes by K-means clustering (Fig. 1a). Clusters 1
(50% of samples) and 2 (41%) contained COVID-19 samples
while cluster 3 contained all normal lung samples as well as three
COVID-19 samples (9%). To understand why the majority of
COVID-19 lung tissues segregated into defined clusters 1 or 2, we
undertook a gene ontology analysis. We identified ISGs as a key
upregulated pathway in COVID-19 autopsy lungs (Table 2),
which was differentially represented in clusters 1 and 2,
respectively (Fig. 1d). Identification of an ISGhigh cluster (Cluster
1, ISGhigh) was surprising since SARS-CoV-2 was recently
proposed to lead to limited ISG induction, yet only in comparison
to other respiratory viruses8. Our data suggest that autopsy lungs
of COVID-19 patients, who died from respiratory failure, showed
two different gene expression patterns with different levels of ISG
activation (ISGhigh and ISGlow).
Clinical differences of COVID-19 patients with an ISGhigh
versus ISGlow lung profile. Patients, whose lung samples all
segregated in the ISGhigh or in the ISGlow subgroups, were called
ISGhigh and ISGlow patients. To investigate whether there were
clinical differences between these two patient groups, we com-
pared their clinical and epidemiological information. The
majority of COVID-19 patients in our cohort (81%) were male
and the average body mass index (BMI) was 31.4. kg/m2. The
patient-level analysis revealed no correlation between sex or BMI
with the ISG patterns (Fig. 1a). All patients in our cohort died
from respiratory failure or multi-organ failure including failure of
the respiratory system, independent of ISG subgrouping (Sup-
plementary Table 1). When we analyzed comorbidities and
autopsy findings, we found that 5 out of 7 (71%) ISGlow patients,
but none of the ISGhigh patients had an autoptic finding of a
thromboembolic event in the lungs and/or disseminated
Table 1 Clinical data of all patients.
Characteristics N or x % or range
COVID-19 cohort (16 patients)
Time between
symptoms and death
7.4 d 0–20 d
Hospitalization 5.6 d 0–13 d
Post mortem interval 28.4 h 11–67 h
Age 75 y 53–96 y












Renal failure 6 37.5%
Laboratory results




Ferritin 18,037.71 µg/l 1025.00–228,225.00 µg/l
Procalcitonin (PCT) 1996.92 µg/l 0.47–5300.00 µg/l
Lactate
dehydrogenase (LDH)
870.42 U/l 256.00–5267.00 U/l








Listed laboratory results correspond to the highest (LDH, cTnT), latest
(IL6, ferritin, PCT), or last value before administration of ACTEMRA/
Tocilizumab (CRP)
Control cohort (6 patients)
Post mortem interval 31.4 h 25–46 h
Age 81.3 y 63–104 y
Sex M 5: F 1
Cohort of patients with other infections (4 patients)
Post mortem interval 31.5 h 12–79 h
Age 79.5 y 58–81 y
Sex M 2: F 2
Patients were suffering from other infections of the lung (bacterial or
viral pneumonia). Detailed analysis of individual pathogens is shown in
Fig. 2
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intravascular dissemination (DIC) indicating abnormally acti-
vated blood coagulation (hypercoagulability) exclusively in ISGlow
patients (Supplementary Table 1). COVID-19-associated coagu-
lopathy was unlikely to contribute to the rapid exacerbation of
pulmonary COVID-19 since this diagnostic criterion was only
observed in patients displaying the ISGlow phenotype. Most
notably, when we compared the hospitalization time between the
patients with different ISG lung profiles, we found a significantly
longer hospitalization time for ISGlow patients from admission to
death compared to ISGhigh patients (Fig. 1e). Of note, we did not
find differences in the anamnestic onset of disease symptoms
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nasopharyngeal swab to hospitalization or death between ISGhigh
and ISGlow patients. To exclude bacterial and viral super-
infections as a confounder of clinical course, we performed
whole-genome sequencing on all samples to detect bacterial and/
or viral DNA. Bacterial superinfections were found in three lung
tissue samples, in 3/16 COVID-19 patients, that were equally
distributed among the different groups (Fig. 2a–e). Based on the
limited number of samples with evidence of bacterial super-
infection, there was no correlation with clinical subgroups or the
duration of the disease.
Taken together, expression of the ISGhigh profile in COVID-
19 lungs is associated with early lethal outcome, and the ISGlow
profile is associated with coagulopathies and later lethal
outcomes. Although autopsy studies do not allow for long-
itudinal analyses, our observation of distinct immunological
patterns of COVID-19 lungs at different times after hospita-
lization is very suggestive of a natural disease course of COVID-
19 in lungs from an ISGhigh profile to an ISGlow profile,
consistent with a longitudinal study in peripheral blood
showing that ISG expression was high in early COVID-19
and declined later9.
Immune microenvironment characteristics of the ISGhigh and
ISGlow COVID-19 lung profiles. In line with a recent study
showing a correlation of ISG expression and viral load in naso-
pharyngeal swabs10, expression of ISGs was positively correlated
with pulmonary viral load (Fig. 3a), and immunohistochemical
staining confirmed the presence of SARS-CoV-2 nucleocapsid
protein in ISGhigh lungs, mainly localized to pneumocytes
(Fig. 3b).
SARS-CoV-2 induces a strong antiviral immune response.
Therefore, we analyzed frequencies of specific immune cells in the
lungs by computational image analysis. T cells (CD3+) of the
CD4+ and CD8+ lineages, B cells (CD20+), and macrophages
(CD68+) were selectively enriched in lung tissues from ISGlow
patients (Figs. 3c, d and 4a, b). A strong enrichment for CD68+
and CD163+monocytes in lung tissue was observed with a spatial
correlation of stains for both markers indicating co-expression.
Since circulating monocytes in COVID-19 patients co-express
CD68 and CD163, it was not surprising that CD68 and CD163
expression in lungs followed a similar pattern11 (Fig. 3c, d).
Surprisingly, CD123+ plasmacytoid dendritic cells (pDCs) did
not show elevated frequencies in ISGhigh lungs (Fig. 4a, b), and
our analysis did not allow us to identify the upstream trigger of
ISGs in lungs.
Innate cytokines have been proposed to contribute to an
adverse outcome of COVID-1912 and cytokines are highly
expressed in BALs of COVID-19 patients4. Therefore, we
investigated the expression of a pro-inflammatory cytokine
signature (TNF, IL1B, IL6, CCL2, IFNA17, IFNB1, CXCL9,
CXCL10, CXCL11) in lung samples from lethal COVID-19,
which contains genes that are upregulated in plasma and/or BAL
of severe COVID-19 patients4, 12, and type I interferons, which
are deregulated in COVID-198. This pro-inflammatory gene
signature was significantly enriched in the ISGhigh subset (p=
0.0061) (Fig. 5a). Activated CD8+ T cells are essential for the
elimination of coronaviruses13, 14. Therefore, we defined and
investigated an activated cytotoxic T cell signature (CD38, GZMA,
GZMB, CCR5) consisting of CD8+ T cell markers that are
associated with severe COVID-19 infection15, 16, and we found
that it was inversely correlated to viral counts, particularly in
ISGlow cases (Fig. 5b). This suggests that activated CD8+ T cells
may indeed contribute to the elimination of SARS-CoV-2 in the
lungs.
Fig. 1 ISGhigh and ISGlow are two gene expression profiles in COVID-19 autopsy lungs. a Heatmap showing K-means clustering of COVID-19 and normal
lung samples based on expression levels of deregulated genes in COVID-19 versus normal lungs. b Comparison of upregulated and downregulated genes in
lung samples from COVID-19 patients, normal lung samples, and samples from other infectious lung pathologies. c Principal component analysis (PCA) of
COVID-19 and non-COVID-19 lung samples reveals segregation in two distinct groups based on diagnosis and viral load. d ISG signature expression in
clusters 1 and 2 of COVID-19 lungs defines two profiles of COVID-19 autopsy lungs termed ISGhigh and ISGlow. Study patients with unambiguous sample
segregation in either Cluster 1 or 2 were assigned the corresponding ISG activation label ISGhigh and ISGlow, respectively (n= 31 independent samples). e
Hospitalization time in ISGhigh patients versus ISGlow patients (n= 14 independent samples). ISGhigh samples, red; ISGlow samples, blue. Box-plots
elements indicate the median (center line), upper and lower quartiles (box limits). Whiskers extend to the most extreme value included in 1.5× interquartile
range. Groups were compared using a two-sided Wilcoxon rank-sum test.
Table 2 Gene ontology enrichment analysis of genes upregulated in COVID-19 samples.
ID Description GeneRatio BgRatio p-value p.adjust
GO:0034340 Response to type I interferon 17/66 30/379 3.70E−07 0.000158
GO:0060337 Type I interferon signaling pathway 17/66 30/379 3.70E−07 0.000158
GO:0071357 Cellular response to type I interferon 17/66 30/379 3.70E−07 0.000158
GO:0051607 Defense response to virus 21/66 44/379 5.53E−07 0.000177
GO:0098542 Defense response to other organism 25/66 71/379 3.85E−05 0.009888
GO:0009615 Response to virus 21/66 57/379 9.79E−05 0.020960
GO:0045069 Regulation of viral genome replication 10/66 18/379 1.87E−04 0.034381
GO:1903900 Regulation of viral life cycle 11/66 22/379 2.95E−04 0.042931
GO:0045071 Negative regulation of viral genome replication 8/66 13/379 3.57E−04 0.042931
GO:1903901 Negative regulation of viral life cycle 8/66 13/379 3.57E−04 0.042931
GO:0048525 Negative regulation of viral process 9/66 16/379 3.68E−04 0.042931
GO:0051603 Proteolysis involved in cellular protein catabolic process 7/66 11/379 6.71E−04 0.071789
GO:0050792 Regulation of viral process 12/66 28/379 9.17E−04 0.088399
GO:0019079 Viral genome replication 10/66 21/379 9.64E−04 0.088399
GO:0043901 Negative regulation of multi-organism process 9/66 18/379 1.16E−03 0.099123
Significance calculated with hypergeometric test, fdr corrected.
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Taken together these data show that COVID-19 autopsy lungs
with an ISGhigh profile show high virus titers, high local
expression of innate cytokines, and weak immune cell infiltration,
while COVID-19 lungs with an ISGlow profile show low virus
titers, lower expression of innate cytokines, and strong immune
cell infiltration. This pattern could indicate expression of the lung
ISGhigh profile at an earlier, innate disease stage, i.e., at a time
when the virus is not yet controlled, and expression of the ISGlow
profile at a later disease stage, i.e., after T cell priming.
The ISGhigh and ISGlow lung immunoprofiles correlate with
morphological changes. To investigate the potential immuno-



































































































































































































































































































































































































































































Fig. 2 Co-infections in COVID-19 lungs identified by WGS metagenomics. No differences in co-infections in ISGhigh and ISGlow COVID-19 lungs identified
by WGS metagenomics. a Total number of reads generated for each sample. b Percentage of reads and c absolute numbers of reads not mapping to the
human genome (GRCh37 hg19) (n= 34 independent samples). Box-plots elements indicate the median (center line), upper and lower quartiles (box limits).
Whiskers extend to the most extreme value included in 1.5× interquartile range. d Bacterial and e viral co-infections across lung samples, WGS metagenomic
analysis. Purple dots, numbers of reads sufficient for identification of non-human species. Samples are ordered by increasing the SARS-CoV-2 viral load in
both the ISGlow and the ISGhigh group. Stacked bars, the relative abundance of the most common species. Gray bars represent frequent species, colored bars
show pathogenic species. *One COVID-19 patient (C3) clustered in the normal control group. ISGhigh samples, red; ISGlow samples, blue.
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ISG profiles in COVID-19 post mortem lungs were associated
with specific histomorphological features of fatal COVID-19.
Diffuse alveolar damage (DAD) was mostly found in ISGlow
patients (Fig. 5c), but intra-alveolar hemorrhage (IAH) was not
associated with lung ISG status.
As some cytokines were proposed to contribute to the decline
of COVID-19 patients, we analyzed whether expression of the
above-defined pro-inflammatory cytokine signature was asso-
ciated with IAH, but this was not the case (Fig. 5d). However,
within this cytokine signature, we identified co-regulated
subgroups (IL1B/IL6/TNF, IFNB1/IFNA17, CCL2/CXCL9/
CXCL19/CXCL11) (Fig. 5e). Of these, the CXCL9/10/11 sub-
signature was positively associated with IAH (Fig. 5f–i). This is in
line with observations that these chemokines compromise
endothelial integrity via CXCR317, and that CXCL10 is a key
determinant of severe COVID-1918. Interestingly, basal levels of
CXCL9 or CXCL10 are elevated in elderly, hypertensive, and
obese individuals, who were strongly represented in our autopsy
cohort (Table 1 and Supplementary Table 1) and are predisposed
to severe COVID-1919, 20.
It has been proposed that infiltrating monocytes and macro-
phages have a role in lung damage4, 21. In support of this data, we
found CD68+ macrophage infiltrates to be positively associated
with DAD (Fig. 5j). In addition, DAD was associated with the
activated cytotoxic T cell signature (p= 0.0022) (Fig. 5k), yet not
with the overall numbers of pulmonary CD8+ T-cells (Fig. 5l).
This raises the possibility that activated CD8+ T cells contribute
to DAD as they eliminate the virus from the infected lungs. None
of the above pulmonary cytokine sub-signatures, however, was
positively associated with DAD (Fig. 5m–p), suggesting that none
of these cytokines drives lung pathology directly.
In summary, we did not find distinct features of lung damage
in ISGhigh patients, suggesting that extra-pulmonary factors may
contribute to mortality in these patients. However, ISGlow
patients show prominent DAD, associated with peri-alveolar foci
of CD68+ macrophages and an activated T cell signature. Local
expression of most cytokines did not correlate to lung damage,
except for CXCL9/10/11, which correlated to IAH (p= 0.018)
(Fig. 5i). Based on studies that associated serum CXCL10 levels





























































































Fig. 3 Virological and cellular characteristics of the ISGhigh and ISGlow COVID-19 lung profiles. a Correlation of viral load and ISG expression in COVID-
19 lungs. Solid lines connect sample points from the same patient. The dotted line shows a regression for all samples, and the gray area delimits the 95%
confidence intervals around it (Pearson’s correlation= 0.83, adjusted R-squared= 0.68, p-value= 1.66e−08). b Representative immunohistochemistry for
SARS-CoV-2 on ISGhigh and ISGlow COVID-19 lung samples and controls. Size bar 100 μm. At least two different tissue blocks from different areas of the
lungs were evaluated for each case. c Frequencies of immune cells on ISGhigh and ISGlow COVID-19 lung sections and controls. (n= 33 for CD3 and CD8, n
= 32 for CD68, n= 30 for CD163). Box-plots elements indicate the median (center line), upper, and lower quartiles (box limits). Whiskers extend to the
most extreme value included in 1.5× interquartile range. Groups were compared using a two-sided Wilcoxon rank-sum test. d Representative H&E stains
and immunohistochemistry (CD3, CD8, CD68, CD163) of ISGhigh and ISGlow COVID-19 lungs and controls, size bar 500 μm. At least two different tissue
blocks from different areas of the lungs were evaluated for each case. ISGhigh samples, red; ISGlow samples, blue.
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whether serum levels of these cytokines predict a specific pattern
of lung damage.
The ISGlow lung profile shows signs of tissue regeneration and
T cell exhaustion. Since ISGlow lung samples were derived from
patients with a longer disease course, we investigated specific
pathways of local immune regulation and tissue regeneration.
ISGlow lung samples expressed elevated p53 and Ki67 (Figs. 1a
and 6a), i.e., reactive markers indicating lung remodeling in
DAD22.
Since we found local upregulation of C1QA (p= 0.017) and
C1QB (p= 0.0012) specifically in ISGlow lungs (Figs. 1a and 6b),
we hypothesized that complement activation may further
contribute to lung damage in these patients. Consistently, we
found strong staining for C3d and C5b-9 complex deposition in
lung tissue indicating complement activation in the lungs of
ISGlow patients (Fig. 6c). Since C1Q also restrains antiviral CD8+
effector T cell responses23, it may contribute to the local
regulation of effector T cells. In line with previous observations24,
we found a higher frequency of CD8+PD1+ T-cells in the ISGlow
subgroup (p= 0.001), potentially indicative of T cell exhaustion
(Fig. 4a, b).
Overall our results identify two patterns of pulmonary
COVID-19 disease that lead to death from respiratory failure.
Patients of the ISGhigh subgroup die early with high viral loads
and high cytokine and ISG expression levels in the lungs. Their
lungs are morphologically relatively intact, and our data do not
identify a uniform pathomechanism underlying lethal outcome,
although some show CXCL9/10/11-associated IAH (Fig. 5i). It is
possible that the direct cytopathic effect of SARS-CoV-2 on
alveolar epithelial cells may have contributed to the lethal
outcome. The distinct ISGlow group of patients dies later, with
low viral loads in the lungs, low local expression of cytokines and
ISGs, yet strong infiltration of pulmonary tissue by CD8+ T cells
and macrophages, which both correlate to the severity of DAD
and local complement activation. Some of these patients show






































































Fig. 4 Immune cell infiltrates on COVID-19 lung sections. a Frequencies of immune cells on ISGhigh and ISGlow COVID-19 lung sections and controls (n=
33 for CD4 and CD20, n= 31 for CD123, n= 32 for CD8/PD1). Box-plots elements indicate the median (center line), upper and lower quartiles (box limits).
Whiskers extend to the most extreme value included in 1.5× interquartile range. Groups were compared using a two-sided Wilcoxon rank-sum test. b
Representative immunohistochemistry (CD4, CD20, CD123, CD8/PD1) of ISGhigh and ISGlow COVID-19 lungs and controls, size bar 500 μm. At least two
different tissue blocks from different areas of the lungs were evaluated for each case. ISGhigh samples, red; ISGlow samples, blue.
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Fig. 5 Correlation of ISGhigh and ISGlow lung immunoprofiles with morphological changes. a Expression of a cytokine signature (TNF, IL-1B, IL6, IFNA17,
IFNB1, CCL2, CXCL9, CXCL10, CXCL11) in ISGhigh and ISGlow COVID-19 lung samples. This pro-inflammatory cytokine signature was significantly enriched in
the ISGhigh subset (n= 31 independent samples). b Inverse correlation of viral load and activated CD8+ T cell signature (CD38, GZMA, GZMB, CCR5). Solid
lines connect sample points from the same patient. The dotted line shows a regression for all the samples, and the gray area delimits the 95% Confidence
Intervals around it (Pearson’s correlation=−0.5, adjusted R-squared= 0.22, p-value= 0.005). c Association of DAD stage with ISG expression (n= 31
independent samples). d Association of the pro-inflammatory cytokine signature with intra-alveolar hemorrhage (IAH) (n= 31 independent samples). e
Pearson’s correlation of pro-inflammatory cytokines in the cytokine signature indicates the presence of co-regulated cytokines. f–i Association of cytokine
signatures in ISGhigh and ISGlow COVID-19 lung samples with IAH. Association of: f Median IL6, TNF, IL1B expression. g Median IFNA17, IFNB1 expression. h
Median CCL2 expression. i Median CXCL9/10/11 expression in ISGhigh and ISGlow COVID-19 lung samples versus IAH. Only the CXCL9/10/11 sub-signature
was positively associated with IAH (n= 31 independent samples). j Association of CD68+ macrophage infiltrates with DAD (n= 27 independent samples).
k Association of DAD stage with activated CD8+ T cell signature (n= 31 independent samples), l with CD8+ T cell counts (n= 29). m–p Association of
cytokine signatures in ISGhigh and ISGlow COVID-19 lung samples with DAD stage. Association of: m Median IL6, TNF, IL1B expression. n Median IFNA17,
IFNB1 expression. o Median CCL2 expression. p Median CXCL9/10/11 expression in ISGhigh and ISGlow COVID-19 lung tissue with DAD stage (n= 31
independent samples). ISGhigh samples, red; ISGlow samples, blue. All box-plots elements indicate the median (center line), upper and lower quartiles (box
limits). Whiskers extend to the most extreme value included in 1.5× interquartile range. Groups were compared using a two-sided Wilcoxon rank-sum test.
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coagulopathies. Altogether this patient group appears to suffer
from severe pulmonary immunopathology. Based on the time
after hospitalization, and based on knowledge about the general
course of coronavirus infections14, our data suggest that patients
expressing an ISGlow profile in their lungs might have undergone
a previous ISGhigh phase, and it is possible that the initial
infectious dose and individual predisposition defines when and
whether a patient dies of COVID-19 lung disease (Fig. 6d).
Discussion
Here we describe two immunopathological patterns in the lungs
of fatal COVID-19 patients based on ISG expression. The ISGhigh
pattern is observed in patients, who die early after hospitalization
and is characterized by high viral load and high levels of pro-
inflammatory cytokines, yet relatively intact lung morphology,
while the ISGlow pattern is characterized by low viral load,
massive lung damage, marked lung immune cell infiltrates, and
late death. Our findings are consistent with epidemiological data
showing two peaks of mortality25, and another study of four
COVID-19 autopsies, where one patient died early after hospital
admission, with striking upregulation of pulmonary IL-1b/IL-6 in
lungs and little lung damage, while three patients expressed low
levels of pulmonary cytokines, massive DAD and delayed death26.
Therefore, our study allows us to propose two immunopatholo-
gical stages of pulmonary COVID-19.
The segregation of autopsy lung samples from COVID-19
patients in two groups based on ISG expression contributes to our
understanding of the interferon response against SARS-CoV-2.
Like other coronaviruses, SARS-CoV-2 is particularly sensitive to
type I interferons8, 27. Therefore, and similar to other cor-
onaviruses28, it has evolved strategies to evade the interferon
response, and SARS-CoV-2 leads to relatively weak IFN-I/III
release in host cells at low multiplicities of infection8. This initial
delay of IFN-I/III production may facilitate initial virus replica-
tion in the lungs, as studies with SARS-CoV in mice have shown,
and enable an eventual increase of the IFN-I response and
death14. A similar observation was made for fatal SARS-CoV
infections in humans, which were accompanied by elevated
expression of ISGs29. Since the SARS-CoV-2 receptor ACE2 is
itself an ISG on lung epithelial cells30, virus infection and the
interferon response may promote each other in this phase of the
infection. This may explain the observed correlation of high ISG
expression and high viral load in the lungs and the widespread
presence of SARS-CoV-2 in lung epithelial cells. Together this
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Fig. 6 Molecular characteristics of the ISGhigh and ISGlow COVID-19 lung profiles. a Representative immunohistochemistry for p53 and Ki67. Size bar
100 μm. At least two different tissue blocks from different areas of the lungs were evaluated for each case. b Expression of C1QA and C1QB in ISGhigh and
ISGlow lung samples (n= 31 independent samples). Box-plots elements indicate the median (center line), upper, and lower quartiles (box limits). Whiskers
extend to the most extreme value included in 1.5× interquartile range. Groups were compared using a two-sided Wilcoxon rank-sum test. c Representative
IHC stainings for complement activation products C5b-9 and C3d in ISGhigh, ISGlow COVID-19, and normal control lungs. Size bar 100 μm. At least two
different tissue blocks from different areas of the lungs were evaluated for each case. ISGhigh samples, red; ISGlow samples, blue. d Schematic time course
of COVID-19 lung disease based on lung autopsy findings. Early in the disease, an ISGhigh lung profile is observed, with high viral load, high expression of
cytokines and ISGs, and sparse immune infiltrates. Late in the disease, an ISGlow lung profile is observed, with low viral load, low local expression of
cytokines and ISGs, and strong infiltration of macrophages and lymphocytes. Patients who die early are not able to adequately control SARS-CoV-2, while
patients who die late suffer from DAD and immunopathology. Infectious dose and individual predisposition to mount immune responses likely define
whether or not a patient survives COVID-19. Green line: Relative viral loads, red line: Relative expression of lung ISGs and cytokines, blue line: pulmonary
immune infiltrates and complement deposition. Dark gray area: lethal outcomes, arrows: individual variability.
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The observation of the ISGhigh pattern in COVID-19 autopsy
lungs seems to be at odds with initial observations that critical
COVID-19 patients express on average lower ISGs in blood than
patients with a milder course of disease31. One possible expla-
nation is that the blood ISG status is not directly reflective of the
lung. In support of this idea, BALs from severe/critical patients
showed high proportions of ISGhigh macrophages and high
expression of CXCL9/10/11, IL6, IL-1b, TNF, CCL24, which is
reflective of our ISGhigh phenotype in lung autopsies. An alter-
native explanation for the apparent disconnect of lung and blood
ISG status may come from the overall frequency of the ISGhigh
subtype of critical/fatal COVID-19: ISGs are highly expressed in
the blood of COVID-19 patients during the early, innate phase of
COVID-199, and we show that patients with an ISGhigh status in
lungs die early upon hospitalization. While the early-mortality
subset accounted for 44% of all deaths in our study, epidemio-
logical data from France25 suggest that this early critical subset is
actually smaller: only 15% of patients died early after hospitali-
zation. This percentage is consistent with the study by Hadjadj
et al.31, which detects high ISG expression in the blood of 3/17
(18%) critical COVID-19 patients, yet this signal gets diluted in
the majority of ISGlow critical cases. These two alternative
explanations show how critical it will be to compare gene
expression in the blood and lungs of individual patients at dif-
ferent times of the infection and to identify peripheral biomarkers
for COVID-19 lung status.
ISGlow COVID-19 patients in our study die with classical
features of DAD32, on average 9.1 days after hospitalization. Later
death compared to patients with an ISGhigh pattern and pro-
gressive decline of systemic ISG expression during COVID-199, 33
led us to infer that the ISGlow pattern in lungs reflects a later
phase of pulmonary COVID-19. ISGlow lungs show higher fre-
quencies of T and B lymphocytes, compared to ISGhigh lungs.
None of our fatal cases showed lung lymphocyte counts below
control levels. Therefore COVID-19-associated lymphopenia in
blood24, 34 or spleens3 does not translate into lymphocyte
depletion in infected lungs. Potential reasons are that the infected
lung acts as a potent sink for circulating lymphocytes and that
local proliferation limited recruitment from the blood, as was
shown for CD8+ T cells in BAL of severe patients4. Consistent
with previous observations35, we describe an activated CD8+ T
cell signature in the lungs of ISGlow patients that contain low viral
counts. This suggests that CD8+ T cells are critical for antiviral
protection, and may transition into a protective memory pool, as
observed for SARS-CoV36, 37. In addition, we found elevated
frequencies of CD8+PD1+ cells in ISGlow lungs compared to
ISGhigh lungs, but not above control levels. The observation that
PD1 levels are elevated in peripheral CD8+ T cells of severe
COVID-19 infection, and whether this indicates exhaustion,
remains controversial24, 33. Overall, although we did not have
paired serum antibody levels available, the infiltration pattern of
ISGlow lungs suggested adaptive immune activation.
While our study sheds further light on COVID-19 lung disease,
conclusions on therapy must be drawn with caution. We found
that early after hospitalization, ISGhigh autopsy lungs had uni-
formly high titers of SARS-CoV-2, and others found that viral
loads in swabs and sputum are highest in early COVID-1938. This
could indicate that treatment with compounds that directly
interfere with the SARS-CoV-2 replication cycle, e.g., protease or
polymerase inhibitors, should start early. However, high expres-
sion of ISGs in some lung autopsies raises caution about the use
of IFN-I/III as therapeutics, at least as long as the causes and
consequences of interferon signaling in COVID-19 lungs remain
unclear. We found reduced viral counts in ISGlow patients but did
not identify the moment at which the body is cleared of the virus.
Therefore, our findings of reduced viral loads in ISGlow patients
should not be taken as justification to withhold compounds that
directly interfere with the SARS-CoV-2 replication cycle from
patients. Extending previous work39, we found signs of elevated
complement activation specifically in ISGlow lungs. However, it is
not known whether the complement is synchronously activated
in patient lungs and plasma40. Therefore, our results do not
provide a further step toward personalized patient care but
strengthen the hypothesis that complement inhibitors may show
therapeutic benefit, at least in some COVID-19 patients.
Our study has several limitations. The fact that patients with
the innate/ISGhigh stage die early while patients with the lym-
phocytic/ISGlow profile die late after hospitalization, together with
knowledge about the immune reaction against other cor-
onaviruses, strongly suggests that COVID-19 lung disease pro-
gresses from an ISGhigh to an ISGlow stage (Fig. 6d). However, an
autopsy study is, by design, not longitudinal. Therefore, we do not
have formal proof that all COVID-19 infected ISGlow lungs have
undergone a previous ISGhigh stage. Also, it is unknown why
some patients die early and others late, and individual predis-
position may be one reason. In addition, our focus on the lung
only allowed us to investigate pulmonary factors of patient
mortality, i.e., an overshooting innate immune activation with
IAH in both ISGhigh and ISGlow cases and DAD in ISGlow cases.
No reported cause of death was enriched in ISGhigh or ISGlow
patients, and multi-organ failure was reported as a cause of death
only for two of our patients. Another limitation is that we lack
gene expression data from the blood of autopsy patients or ser-
ological data at the time of death. Therefore, we were not able to
identify peripheral biomarkers predicting specific immunological
profiles in the lung. Finally, we analyzed our lungs with a focused
gene expression set since the quality and quantity of autopsy-
derived RNA is often insufficient for unbiased methods. We
chose to probe this gene expression dataset with pre-defined
cytokine and cytotoxic T cell signatures based on published
information on deregulated genes in COVID-19. This helped us
put our data in perspective to the published literature, yet may
have restricted our analysis. In spite of these technical limitations,
we were able to uncover two novel and distinct immunopatho-
logical profiles in the lungs of fatal COVID-19.
Taken together, our autopsy study sheds light on two distinct
courses of lethal COVID-19 in the lungs. It remains to be seen
whether interferon signaling is only associated with or causally
involved in these disease courses. However, our study strengthens
the notion that interferon signaling is a central determinant of the
pulmonary immune response against SARS-CoV-2.
Methods
Ethics statement. This study was conducted according to the principles expressed
in the Declaration of Helsinki. Ethics approval was obtained in written form from
the Ethics Committee of Northwestern and Central Switzerland (Project-ID 2020-
00629). For all patients, either personal and/or family consent was obtained for
autopsy and sample collection, in line with Swiss law and the above Ethics
approval.
Patients and sample collection. The study is based on the analysis of 16 out of 21
consecutive COVID-19 autopsies performed between March 9th and April 14th
2020 at the Institute of Pathology Liestal and Institute of Medical Genetics and
Pathology Basel, Switzerland. Clinical features including symptoms, course of the
disease, comorbidities, laboratory results, and therapy are listed in Table 1a and
Supplementary Table 1. Detailed autopsy findings for each patient were recently
published, and the identifiers (with the prefix “C”) for each COVID-19 patient are
consistent with the description of this Swiss COVID-19 autopsy cohort6. In this
study, we analyzed formalin-fixed and paraffin-embedded (FFPE) lung tissue of
distinct areas of the lungs of 16 of these COVID-19 patients. All 16 COVID-19
patients had positive nasopharyngeal swabs collected while alive. In all COVID-19
patients, the diagnosis was confirmed by detection of SARS-CoV-2 in postmortal
lung tissues. 5/16 patients were additionally tested by postmortal nasopharyngeal
swabs which were positive for SARS-CoV-2 in all 5 cases.
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As a control cohort, we selected 6 autopsies performed between January 2019
and March 2020 at the Institute of Pathology Liestal (“normal” patients N1–N6).
These control patients died of other, non-infectious causes and had similar age,
gender, and cardiovascular risk profile. Patients with infections were excluded from
this control cohort. Another control cohort consisted of 4 autopsies of patients
suffering from various infections mainly with bacteria affecting the lung (patients
with lung pathology, P1–P4). Details for both control cohorts are listed in Table 1.
SARS-CoV-2 was ruled out for each control patient by PCR-examination of lung
tissue samples.
Nucleic acid extraction. RNA was extracted from up to six sections of FFPE tissue
blocks using RecoverAll Total Nucleic Acid Isolation Kit (Cat No. AM1975,
ThermoFisher Scientific, Waltham, MA, USA). Extraction of DNA from up to
10 sections of FFPE tissue samples was automated by EZ1 Advanced XL (Qiagen,
Hilden, Germany) using the EZ1 DNA Tissue Kit (Cat No. 953034, Qiagen, Hilden,
Germany). The concentration of DNA and RNA were measured with Qubit 2.0
Fluorometer and Qubit dsDNA HS Assay or Qubit RNA HS Assay (Cat Nos.
Q33230 & Q32852, ThermoFisher Scientific, Waltham, MA, USA), respectively.
Quantification of SARS-CoV-2 in FFPE tissue samples. Post mortem viral load
was individually measured in all lung tissue blocks from all patients included in this
study. SARS-CoV-2 was detected in 15 ng of human total RNA using the TaqMan
2019-nCoV Assay Kit v1 (Cat No. A47532, ThermoFisher Scientific, Waltham,
MA, USA), which targets three genomic regions (ORFab1, S Protein, N Protein)
specific for SARS-CoV-2 and the human RNase P gene (RPPH1). The copy
numbers of the SARS-CoV-2 viral genome was determined by utilizing the Taq-
Man 2019-nCoV Control Kit v1 (Cat No. A47533, ThermoFisher Scientific,
Waltham, MA, USA) and a comparative “ΔΔC
т
” method. The control kit contains
a synthetic sample with a defined amount of target molecules for the human
RPPH1 and the three SARS-CoV-2 assays and was re-analyzed in parallel with
patient samples. For each patient sample, this method resulted in individual copy
numbers of the human RPPH1 and the three SARS-CoV-2 targets. Finally, the
mean copy number of the SARS-CoV-2 targets was normalized to 1 × 106 RPPH1
transcripts.
Profiling of immune response by targeted RNAseq. The expression levels of 398
genes, including genes relevant in innate and adaptive immune response and
housekeeping genes for normalization, were analyzed with the Oncomine Immune
Response Research Assay (OIRRA, Cat No. A32881, ThermoFisher Scientific,
Waltham, MA, USA). The OIRRA is a targeted gene expression assay designed for
the Ion™ next-generation sequencing (NGS) platform. Our study focused on the
analysis of rare autopsy tissue samples from COVID-19 patients collected in
clinical routine during the COVID-19 pandemic. An inherent problem for tran-
scriptomic studies of autopsy tissues is that it is often not possible to extract high-
quality RNA in sufficient amounts. To avoid sample dropout due to these reasons,
we decided to use a robust and straightforward targeted gene expression assay
(OIRRA) rather than whole transcriptome analysis. Since the focus of our study
was to investigate the immune profile of the lungs, an immunoprofiling assay was
deemed most appropriate. The OIRRA gene expression assay was originally
designed to interrogate the tumor microenvironment to enable mechanistic studies
and identification of predictive biomarkers for immunotherapy in cancer. The
assay is optimized to measure the expression of genes involved in immune cell
interactions and signaling, including genes expressed at low levels and involved in
inflammatory signaling. The 398 genes covered by this assay are listed in Sup-
plementary Table 2. The accessibility of such commercially available assays could
be an encouragement to hospitals around the world to conduct similar molecular
profiling studies of diagnostic tissue samples from COVID-19 patients, allowing
relatively fast and easy stratification of patients into distinct biological groups as a
starting point for targeted intervention strategies.
The NGS libraries were prepared as recommended by the supplier. In brief, 30
ng of total RNA were used for reverse transcription (SuperScript VILO, Cat No.
11754250, ThermoFisher Scientific, Waltham, MA, USA) and subsequent library
preparation. The libraries were quantified (Ion Library TaqMan Quantitation Kit,
Cat No. 4468802, ThermoFisher Scientific, Waltham, MA, USA), equimolarly
pooled, and sequenced utilizing the Ion GeneStudio S5xl (ThermoFisher Scientific,
Waltham, MA, USA). De-multiplexing and gene expression level quantification
were performed with the standard setting of the ImmuneResponseRNA plugin
(version 5.12.0.1) within the Torrent Suite (version 5.12.1), provided as part of the
OIRRA by ThermoFisher Scientific, Waltham, MA, USA.
Detection of co-infections by whole genome sequencing. To identify potential
pathogens accompanying an infection with SARS-CoV-2, we analyzed the DNA of
the same tissue samples used for detection and profiling of the SARS-CoV-2-
specific immune response. First, 250 ng of genomic DNA was enzymatically
sheared (15 min at 37 °C) and barcoded using the Ion Xpress Plus Fragment
Library Kit (Cat No. 4471269, ThermoFisher Scientific, Waltham, MA, USA).
Subsequently, the libraries were quantified (Ion Library TaqMan Quantitation Kit,
Cat No. 4468802, ThermoFisher Scientific, Waltham, MA, USA) and up to three
libraries were pooled at equimolar levels for analysis with Ion GeneStudio S5xl
(ThermoFisher Scientific, Waltham, MA, USA). Sequencing data for each sample
was analyzed using the CLC genomics workbench (version 20.0.3, Qiagen, Hilden,
Germany) in combination with the microbial genomics module (version 20.0.1,
Qiagen, Hilden, Germany): the raw reads were trimmed by quality (Mott algorithm
with limit 0.05 and a maximum of 2 ambiguous bases per read) and mapped to the
human genome (GRCh37 hg19, match score: 1, mismatch cost: 2, indel opening
cost: 6, indel extension cost: 1). Unmapped reads were analyzed by taxonomic
profiling to identify reads of viral or bacterial origin. The profiling utilized an index
of 11,540 viral genomes with a minimum length of 1000 bp and 2715 bacterial
reference genomes with a minimum length of 500,000 bp, retrieved from the NCBI
Reference Sequence Database (https://www.ncbi.nlm.nih.gov/refseq/; date of
download: 2020-04-02).
Immunohistochemistry. Immunohistochemical analyses for CD3, CD4, CD8,
CD15, CD20, CD68, CD123, CD163, PD1, MPO, p53, Ki67, C3d, and C5b-9 were
performed on all lung tissue blocks used in this study. Antibody stainings are part of
the diagnostic routine at our institution, i.e., negative and positive controls have been
established and validated on tonsil sections for all antibodies used, including isotype
controls for monoclonals. All validation protocols are documented in accreditation
protocol ISO 15189:2012 of our institution and are available upon request. Antibodies,
staining protocols, and conditions are detailed in Supplementary Table 4.
Qualitative and semiquantitative assessment of histopathological lung
damage and neutrophilic infiltration. Hematoxylin and eosin (H&E) and Elastica
van Gieson (EvG) stained sections of all lung tissues used in this study were inde-
pendently evaluated by two experienced and board-certified pathologists (VZ and
KDM) (Supplementary Table 5). Both pathologists evaluated the presence of diffuse
alveolar damage (DAD), and if present, its stage, intra-alveolar edema, and hemor-
rhage. The characteristic three phases or stages of DAD—exudative (1), proliferative/
organizing (2), fibrotic (3)—were assessed as described41. In our cohort of COVID-19
lungs, we observed only DAD stages 1 and/or 2, and the fibrotic phase (3) was not
observed. In addition, both pathologists evaluated the severity of histopathological
changes in COVID-19 lungs (1 = mild/discrete alterations, 2 = moderate, 3 = severe
changes) based on the resemblance between normal and pathologically altered lung
tissues. Parameters that were taken into account included reduction of alveolar air-
filled spaces, typical histologic features of DAD with hyaline membrane formation,
infiltration of lymphocytes, monocytes, and neutrophils into interstitial and alveolar
spaces, type 2 pneumocyte hyperplasia, desquamation of pneumocytes, histologic
features of organizing pneumonia including intra-alveolar fibrin deposition and
fibrosis (acute fibrinous and organizing pneumonia, AFOP)42, 43. The number of
neutrophils per lung tissue section was estimated on H&E stained sections and by
immunohistochemical stains for CD15 and MPO using a three-tiered system (1= few
or no neutrophils, 2 = moderate number of neutrophils, 3 = high number of neu-
trophils). Assessment of the two pathologists was concordant in the vast majority of
cases. Discrepant cases were reviewed by a third pathologist (NW) to reach consent.
Digital image analysis. Slides were digitalized on a 3DHistech™ P1000 slide
scanner at ×400 magnification (3DHISTECH Ltd. Budapest, Hungary). Digital
slide review and quality control were performed by a board-certified pathologist
(VHK). Tissue regions with staining artefacts, folds, or other technical artefacts
were excluded from the analysis. A deep neural network (DNN) algorithm
(Simoyan and Zisserman VGG, HALO AI™ on HALO™ 3.0.311.167, Indica Labs,
Corrales, NM) was trained using pathologist annotations to automatically
localize and measure the area of each lung tissue sample on the digital slides.
Background regions and glass were excluded from the analysis. Mark-up images
for tissue classification were generated and classification accuracy was confirmed
through pathology review. For cell-level analysis, color deconvolution for DAB,
AP, and hematoxylin channels was performed and nuclear segmentation was
optimized using cell-morphometric parameters. Marker-positive cells in stromal
and epithelial regions were quantified. For CD3, CD4, CD8, CD20, CD68,
CD123, CD163, and PD1, staining detection was optimized for the cytoplasmic/
membranous compartment, and marker expression was measured on a con-
tinuous scale at single-cell resolution. For assessment of CD8/PD1 double stains,
color deconvolution was optimized for the separation of DAB (PD1) and AP
(CD8) staining products. Internal controls (non-immune cells) and external
controls (tonsil) were used to calibrate the detection limits and cross-validated
by visual review. For each tissue sample, the total area of lung tissue in mm2, the
absolute number of marker‐positive cells, cell-morphometric parameters, and
staining intensity were recorded.
Identification of SARS-CoV-2 immune response pattern
Gene expression analysis. Samples were included in the study based on the quality
of libraries and alignment performance. Applied inclusion criteria are >1 million
mapped reads, good concentration of libraries, average read length >100 bp, >300
target genes with more than 10 reads. One sample with >1 Mio reads was excluded
from the study because of shorter read length and a low library concentration.
Notably, this sample had the longest time between death and autopsy (72 h) before
analysis. Differential expression analysis was performed using the edgeR package
comparing normal lung samples, COVID-19 samples, and samples from patients
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with other infections. Genes were selected for downstream analyses by fdr <0.05
and |logFC| > 1 for clustering analysis. Clustering analysis was performed using k-
means algorithm and complete linkage. The ideal number of clusters (n= 3) was
chosen based on 30 different algorithms44 and the final clustering derives from the
consensus of 2000 iterations. The expression of gene signatures was calculated as
the median of log2(cpm + 1) of selected genes.
Functional enrichment analysis. Biological processes enrichment was performed
using the enrichGO function of the package clusterProfiler45 setting all the genes
included in the assay as universe.
Statistical analysis and reproducibility. All the analyses and graphical representations
were performed using the R statistical environment software46 and the following
packages: ggplot247, circlize48, ComplexHeatmap49, ggfortify50, reshape251, and fac-
toextra52. Correlation between transcripts and viral counts was performed using
Pearson’s correlation. Association between continuous and categorical data were
tested using the Wilcoxon rank-sum test.
Based on the often non-uniform histopathological appearance of lung samples
from the same patient, transcriptomic, morphologic, or histopathological analyses
were performed at the tissue sample level. Analyses involving patients’ clinical or
demographical data were performed at the patient level and patients in which all
analyzed lung samples expressed an ISGhigh or an ISGlow profile were called ISGhigh
or ISGlow patients.
Box-plots elements indicate the median (center line), upper and lower quartiles
(box limits), and show all the data points. Whiskers extend to the most extreme
value included in 1.5× interquartile range.
The microscopic images are representative of at least two different tissue blocks
from different areas of the lungs that were evaluated for each COVID-19 case. All
data are representative of 34 post mortem lung samples from 16 deceased COVID-
19 patients. At least two different tissue blocks from different areas of the lungs
were evaluated for each case. Results were compared to nine post mortem lung
samples from six patients who died from non-infectious causes.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The data sets generated and analyzed within this study can be accessed in GEO
(GSE151764). Patients’ clinical features are listed in Table 1 and Supplementary
Table 1. Source data are provided with this paper.
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